3/24/2023 0 Comments Synergy pharmaceuticals"With our team's expertise in GI and primary care, we will strengthen our already formidable portfolio of innovative irritable bowel syndrome solutions with the addition of TRULANCE®. We are excited to acquire the assets of Synergy, which we believe will strategically enhance our Salix Pharmaceuticals business and supplement our organic growth in gastroenterology," said Joseph C. "As we continue to transform Bausch Health, we are now pivoting to offense with research investments and strategic acquisitions that augment our core businesses. ![]() (NASD: SGYP) ("Synergy") for a cash purchase price of approximately $195 million and the assumption of certain assumed liabilities, pursuant to the terms of the stalking horse asset purchase agreement previously entered into with the Company (as described below). (NYSE/TSX: BHC) ("Bausch Health" or the "Company") announced today that the Company was selected as the successful bidder to acquire certain assets of Synergy Pharmaceuticals Inc. 26, 2019 /PRNewswire/ - Bausch Health Companies Inc. Public Reporting on Product and Service Safety Issuesīausch Health and Synergy to Seek Bankruptcy Court Approval of Sale on March 1, 2019.Global Quality Management System (GQMS).Submitting a Supplier Diversity Profile. ![]() Auditing, Monitoring and Risk Assessments.Dermatology Products/Aesthetics Devices.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |